-+ 0.00%
-+ 0.00%
-+ 0.00%

Viatris wins Japan approval for Wakix to treat narcolepsy, daytime sleepiness in sleep apnea patients

PUBT·09/16/2026 10:59:40
Listen to the news
Viatris wins Japan approval for Wakix to treat narcolepsy, daytime sleepiness in sleep apnea patients
  • Japan’s health ministry granted Viatris approval for WAKIX (pitolisant) to treat excessive daytime sleepiness tied to obstructive sleep apnea.
  • The clearance also covers narcolepsy type 1 and 2, with or without cataplexy.
  • WAKIX becomes Japan’s first histamine H3 receptor antagonist/inverse agonist approved for these indications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609160659PR_NEWS_USPR_____NE48771) on September 16, 2026, and is solely responsible for the information contained therein.